Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, oral ACTH antagonist, that is in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.

• Revenue in USD (TTM)1.39m
• Net income in USD-258.54m
• Incorporated2008
• Employees290.00

• Location
  Crinetics Pharmaceuticals Inc10222 Barnes Canyon Rd Bldg 2SAN DIEGO 92121-2711United StatesUSA
• Phone+1 (858) 450-6464
• Fax+1 (302) 636-5454
• Websitehttps://www.crinetics.com/